Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension
JC Gillis, A Markham - Drugs, 1997 - Springer
Synopsis Irbesartan inhibits the activity of angiotensin II (AII) via specific, selective non-
competitive antagonism of the AII receptor subtype I (AT 1) which mediates most of the
known physiological activities of AII. In patients with mild to moderate hypertension, once
daily administration of irbesartan 150 or 300mg, with or without adjunctive antihypertensive
agents, provides effective 24-hour BP control. Irbesartan reduced BP to a similar extent to
enalapril and atenolol and to a significantly greater extent than losartan. The combination of …
competitive antagonism of the AII receptor subtype I (AT 1) which mediates most of the
known physiological activities of AII. In patients with mild to moderate hypertension, once
daily administration of irbesartan 150 or 300mg, with or without adjunctive antihypertensive
agents, provides effective 24-hour BP control. Irbesartan reduced BP to a similar extent to
enalapril and atenolol and to a significantly greater extent than losartan. The combination of …
Irbesartan. A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in the Management of Hypertension
JC Gillis, A Markham - Arterial Hypertension, 1999 - journals.viamedica.pl
Irbesartan inhibits the activity of angiotensin II (AII) via specific, selective noncompetitive
antagonism of the All receptor subtype 1 (AT1) which mediates most of the known
physiological activities of AII. In patients with mild to moderate hypertension, once daily
administration of irbesartan 150 or 300 mg, with or without adjunctive antihypertensive
agents, provides effective 24-hour BP control. Irbesartan reduced BP to a similar extent to
enalapril and atenolol and to a significantly greater extent than losartan. The combination of …
antagonism of the All receptor subtype 1 (AT1) which mediates most of the known
physiological activities of AII. In patients with mild to moderate hypertension, once daily
administration of irbesartan 150 or 300 mg, with or without adjunctive antihypertensive
agents, provides effective 24-hour BP control. Irbesartan reduced BP to a similar extent to
enalapril and atenolol and to a significantly greater extent than losartan. The combination of …
以上显示的是最相近的搜索结果。 查看全部搜索结果